Brian Ramnaraign, MD

home / authors / brian-ramnaraign-md

Articles

Brian H. Ramnaraign, MD

Dr Ramnaraign on Retrospective Data For irAEs in Older Patients With Kidney Cancer

Brian Ramnaraign, MD
November 11th 2023

Brian H. Ramnaraign, MD, discusses findings from a single-institution review of the incidence of immunotherapy-related toxicities in older patients with kidney cancer.

Read More

Brian Ramnaraign, MD

Dr. Ramnaraign on the Investigation of Atezolizumab Plus Tivozanib in CRPC

Brian Ramnaraign, MD
February 20th 2023

Brian Ramnaraign, MD, discusses the investigation of atezolizumab with tivozanib in castrate-resistant prostate cancer.

Read More

Brian Ramnaraign, MD

Dr. Ramnaraign on the Evaluation of Atezolizumab Plus Tivozanib in GI Malignancies

Brian Ramnaraign, MD
February 1st 2023

Brian Ramnaraign, MD, discusses the evaluation of atezolizumab plus tivozanib in a phase 1b/2 trial in patients with pancreatic, gallbladder, and bile duct cancers.

Read More

Brian Ramnaraign, MD

Dr. Ramnaraign on Sequencing IO and TKI Combinations in Metastatic RCC

Brian Ramnaraign, MD
March 8th 2022

Brian Ramnaraign, MD, discusses sequencing immunotherapy and tyrosine kinase inhibitor combinations in metastatic renal cell carcinoma.

Read More

Brian Ramnaraign, MD

Dr. Ramnaraign on Current Treatment Guidelines for First-Line Metastatic RCC

Brian Ramnaraign, MD
November 18th 2021

Brian Ramnaraign, MD, discusses current first-line treatment guidelines for patients with metastatic renal cell carcinoma. 

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need